




Luca Massacesi
Professore Ordinario Neurologia
Dipartimento Neuroscienze Farmaco e Salute Bambino Università di Firenze
Direttore SOD Neurologia 2, Azienda Ospedaliero-Universitaria Careggi



Al Gruppo di Studio Neuroimmunologia della SIN

Firenze 21 Gennaio 2021

Carissime/i,

come sapete il Consiglio Direttivo della SIN ha recentemente autorizzato le attività del nostro Gruppo di Studio per un altro quinquennio e pertanto ha convocato le elezioni per il ruolo di Coordinatore, che si svolgeranno il giorno 25 Febbraio prossimo. Il Coordinatore rimarrà in carica due anni eventualmente rinnovabili.

Pertanto con la presente comunico la disponibilità a coordinare il Gruppo di Studio Neuroimmunologia della SIN per il prossimo biennio. Ho condiviso la mia scelta con il Coordinatore uscente Marco Salvetti - che ringrazio per l'eccellente lavoro svolto per tutti noi - e con altri possibili autorevoli candidati, pervenendo alla conclusione che l'esperienza di Coordinatore dell'analogo gruppo di studio della European Academy of Neurology (EAN) denominato Scientific Panel Neuroimmunology, che ho svolto dal 2016 (appena conclusa), potrebbe portare un valore aggiunto al ruolo per il quale ora chiedo il vostro appoggio.

A questo fine allego il mio CV, in particolare per i più giovani che forse mi conoscono meno, da cui è possibile ricavare il contributo da portato nella mia carriera a questo settore.

In breve, fino dai primi anni '80 - dalla laurea in Medicina e Chirurgia conseguita con una tesi sull'encefalite allergica sperimentale (EAE), di cui fu Relatore il caposcuola dell'attuale neurologia fiorentina, Luigi Amaducci -, le patologie immuno-mediate del sistema nervoso sono state il mio principale interesse di ricerca. Da allora dopo essermi specializzato in Neurologia ed anche in Allergologia e Immunologia Clinica, ho approfondito la neuroimmunologia negli USA a Bethesda (Md) presso i National Institutes of Health di con Dale McFarlin ed Henry MacFarland pionieri di questa disciplina fino dagli anni '70 e soprattutto a Boston presso l'Università di Harvard, collaborando con Stephen Hauser, con il quale ho sviluppato il noto modello di EAE nel marmoset che negli anni successivi ha contribuito in maniera rilevante all'avanzamento delle conoscenze sull'immunopatogenesi della sclerosi multipla (SM). Da allora, la mia produzione scientifica è sempre stata focalizzata prevalentemente su argomenti di neuroimmunologia e al mio rientro in Italia nei primi anni '90, tra le altre attività ho avuto il privilegio di coordinare il primo progetto dell'Unione Europea sulla risposta linfocitaria T nella SM e negli anni 2000 uno dei primi RCT indipendenti finanziati da AIFA in campo neurologico, sull'efficacia comparativa tra un farmaco "disease modifying" per la SM orfano ed uno *brand*. Tale esperienza, che secondo AIFA aveva prodotto risultati di grande rilevanza per il Servizio Sanitario Nazionale dimostrando anche la fattibilità di ricerca clinica sui farmaci indipendente da interessi privati, ha contribuito ad indurre tale agenzia ad includermi nei diversi comitati scientifici di consulenza sui farmaci per le patologie neurologiche insediati dal 2009 al 2017 e nel 2009 a propormi all'European Medicine Agency come membro italiano dello Scientific Advisory Group (SAG)-Neurology, di cui faccio parte tuttora. Segnalo che a causa di questa nomina da allora le mie attività scientifiche ed i rapporti con Aziende private del settore sono state e sono tuttora costantemente monitorate da tali Agenzie per l'eventuale presenza di conflitti di interesse incompatibili con questi ruoli. Dal 2010, in occasione di un anno sabbatico passato di nuovo presso i National Institutes of Health, ho sviluppato anche nella SM l'uso di metodi ricerca MRI - prima utilizzati prevalentemente

Luca Massacesi
Professore Ordinario Neurologia
Dipartimento Neuroscienze Farmaco e Salute Bambino Università di Firenze
Direttore SOD Neurologia 2, Azienda Ospedaliero-Universitaria Careggi



nella EAE -, per la valutazione in vivo della neuropatologia di malattie infiammatorie del SNC, quindi come strumento di studio dei meccanismi immunopatogenetici effettori a livello cerebrale. Infine, ma non meno importante, da circa due anni su mandato dell'EAN svolgo il ruolo di co-coordinatore di una Task Force di esperti finalizzata a redigere linee guida per il trattamento delle encefaliti autoimmuni che dovrebbe concludere i lavori entro l'anno in corso. Se quindi mi riterrete qualificato al servizio di Coordinatore delle attività del Gruppo di Studio di Neuroimmunologia della SIN, vi invito a prendere in considerazione la mia candidatura.

Cordiali Saluti,

Luca Massacesi



Curriculum Vitae Europass

Personal Data

Name **Luca Massacesi**
Address Department of Neurosciences, Drug and Child Health, University of Florence,
Neurology II, Careggi University Hospital - University of Florence
Largo Brambilla 3 - 50134, Florence, Italy

Phone +39 0557947927- +39 3478781975
E-mail massacesi@unifi.it
Nazionalità Italian
Date of Birth 30.11.1954

CURRENT POSITION

- **Name of the employer** **University of Florence, Florence, Italy**
 - Sector Department of Neurosciences, Drug and Child Health
 - Position held Full professor of Neurology

- **Name of the employer** **Careggi University Hospital - University of Florence**
 - sector Department Neurology II
- Occupation or position held Director

MAIN SKILLS

- Principal areas of expertise
 - Clinical care, research and teaching in Neurology and Neuroimmunology with main interests in multiple sclerosis, encephalitis, CNS vasculitis and in general in inflammatory diseases of the Nervous System.
 - Immunotherapies including autologous hematopoietic stem cell transplantation.
 - Imaging of the Central Nervous System.
 - Management and evaluation of clinical studies.
 - Drug evaluation and drug regulatory processes.
 - Clinical Management and Governance.
 - Ethic issues of clinical and preclinical research.

WORK EXPERIENCE (ACADEMIC)

- **Dates (from – to)** 1984 -1990
- **Name of employer** Italian National Research Council and Clinica Malattie Nervose e Mentali, University of Florence
 - Sector Neurology
- Occupation or position held Research fellow
- Main activities and responsibilities Research

- **Dates (from – to)** 1988-1991
- **Name and address of employer** Massachusetts General Hospital - Harvard University, Boston, Ma, USA
 - Sector Neuroimmunology Unit, Dept. of Neurology
- Occupation or position held *Postdoctoral fellow.*
- Main activities and responsibilities Research

- **Dates (from-to)** 1995-2001
- **Name of employer** University of Florence – Florence, Italy
 - Sector Department of Neurological e Psychiatric Sciences,
- Occupation or position held Assistant Professor (equivalent) of Neurology
- Main activities and responsibilities Research, teaching, clinical activity

- **Dates (from-to)** 2001-2005
- **Name of the employer** University of Florence, Florence, Italy
 - Sector Department of Neurological e Psychiatric Sciences
- Occupation or position held Associate Professor of Neurology
- Main activities and responsibilities Research, teaching, clinical activity

- **Dates (from-to)** 2005- today
- **Name of the employer** University of Florence, Florence, Italy
- Type of business or sector Department of Neurological e Psychiatric Sciences-University of Florence (from 2013, Dept. of Neurosciences Drugs anch Child Health)
- Occupation or position held Full Professor of Neurology
- Main activities and responsibilities Research, teaching, clinical activity

- **Dates (from-to)** 2008-2012
- **Name of the employer** University of Florence

- Type of business or sector Ph.D. Program in Neurosciences
 - Occupation or position held Director
 - Main activities and responsibilities Research teaching, Research management.
 - Dates (from – to) 2008-2012
 - Name and address of employer University of Florence
- Type of business or sector Resident Program in Neurophysiopathology
 - Occupation or position held Director
 - Main activities and responsibilities Teaching and tutorship of clinical activity
 - Dates (from – to) 2009-2010
 - **Name of the employer** National Institute of Health, Bethesda, MD, USA
- Type of business or sector NINDS, Neuroimmunology Branch
 - Occupation or position held *Adjunct Scientist*
 - Main activities and responsibilities Research
 - Dates (from – to) 2010-2013
 - **Name of the employer** National Institute of Health, Bethesda, MD, USA
 - Sector NINDS, Neuroimmunology Branch
 - Occupation or position held *Special Investigator*
 - Main activities and responsibilities Research
 - Dates (from – to) 2016-2020
 - **Name of the employer** University of Florence
 - Sector Council of Discipline
 - Occupation or position held member
 - Main activities and responsibilities Consulting the University of Florence Rector on discipline violations of Professors and Researchers.
 - Dates (from-to) 2018-today
 - **Name of the employer** University of Florence-Careggi University Hospital
 - Sector Conflict of interest evaluation committee (COVACI)
 - Occupation or position held Delegate of the University of Florence Rector.
 - Main activities and *Evaluation of potential conflict of interests of Staff Physicians and of*

responsibilities *University Professors and Researchers involved in clinical activities.*

- Dates (from-to) *2020- today*
- **Name of the employer** University of Florence
 - Sector Academic Senate
- Occupation or position held Biomedical Area representative
Control and collaboration to programming, regulating, and coordinating the activities of the Florence University Government.
- Main activities and responsibilities

WORK EXPERIENCE (CLINICAL)

Professional Registration *Ordine Medici of Florence, 07156*

- Dates (from – to) 1983-1984
- **Name of employer** Italian Army-Florence Army Hospital
 - Sector Army Health Corp
- Occupation or position held *Lieutenant*
Staff Physician - Neurology Dept.
- Main activities and responsibilities

- Dates (from – to) *1991-2008*
- **Name of employer** Careggi University Hospital
 - Sector Department of Neurology 1
- Occupation or position held Staff Neurologist
clinical activity, clinical research, teaching,
- Main activities and responsibilities

- Dates (from – to) *2008- today*
- **Name of the employer** Careggi University Hospital
 - Sector Department Neurology 2:
 - Occupation or position held Director
clinical activity, clinical management, clinical research, teaching,
- Main activities and responsibilities

- Dates (from – to) 2012-2014
- **Name of the employer** Careggi University Hospital
 - Sector Department of Neurosciences
- Occupation or position held Director
- Main activities and responsibilities clinical governance, clinical management

EDUCATION AND ACADEMIC BACKGROUND

- Date 1975-1982
- **Name and type of organization providing education and training** University of Florence
 - Principal subjects/occupational skills covered School of Medicine and Surgery
 - Title of qualification awarded Degree in Medicine and Surgery
 - Level in national classification 110/110 cum laude
- Date 1982-1986
- **Name and type of organization providing education and training** University of Florence
 - Principal subjects/occupational skills covered Resident Program in Neurology
 - Title of qualification awarded Board Certificate in Neurology
 - Level in national classification 70/70 cum laude
- Date 1988-1990
- **Name and type of organization providing education and training** University of Florence
 - Principal subjects/occupational skills covered Resident Program in Clinical Immunology
 - Title of qualification awarded Board Certificate in Clinical Immunology
 - Level in national classification 70/70 cum laude
- Date 1982

- • **Name and type of organization providing training** Stanford University, Palo Alto. Ca, USA.,
 - sector Neurology Department, Laboratory of Neurochemistry
- Occupation or position held *visiting fellow.*
 - Main activities and responsibilities research
- Date 1985
- **Name and type of organization providing training** National Institute of Health, Bethesda, MD, USA
 - sector NINDS, Neuroimmunology Branch
- Occupation or position held *visiting fellow*
 - Main activities and responsibilities research

Further scientific activities

- 1993-1994 - **European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)** executive committee: member
- 1993-2014 - **Italian Multiple Sclerosis Society (AISM)** Scientific Committee/Research and Evaluation Committee.; member
- 1994-1997 - **R&D program of the del DG XII EU Commission** Project Leader of the Concerted Action: "T-cell Autoimmunity in Multiple Sclerosis",
- 1997-1999 - **Studio multicentrico italiano dell'Associazione Italiana Sclerosi Multipla (AISM):** "Centralized Facility for genetic studies in Multiple Sclerosis". Coordinator
- 1997-2013 - **Florence University-Magnetic Resonance Interdepartmental Center,** steering committee: member
- 1999-2000 - **International Federation of Multiple Sclerosis Societies:** Scientific Program Committee; member of the Medical Advisory Board.
- 1995-2001 - **Biomedical Primate Research EU Large Scale Facility,** Rijswijk, Nederland; member of the Scientific Committee.
- 1998-2002 - **Multicentric Italian Randomized Clinical Trial:** "Open randomized clinical study on different doses of β IFN1 α , also in association with Azathioprine, in patients with relapsing-remitting multiple sclerosis": National coordinator
- 2006-2011 - **Non-profit multicentric clinical RCT, sponsored by the Italian Medicine Agency (AIFA)** "Randomized controlled study of Azathioprine versus Interferon beta in relapsing-remitting multiple sclerosis". Scientific coordinator.
- 2010-2016 - **Data and Safety monitoring board (DSMB) of the National Institutes of Health phase II intramural clinical study:** Investigating the mechanism of action of DAC HYP (Daclizumab) in the treatment of highly inflammatory multiple sclerosis: Chairman.
- 2009-2016 - **Agenzia Italiana del Farmaco (AIFA),** Rome, Italy; Scientific Advisory Committee on Neurosciences: member.
- 2011-2018 - **Non-profit multicentric clinical trial funded by the Emilia-Romagna regional Government:** "Multicentric RCT for the evaluation of efficacy and safety of extracranial vein unblocking in the treatment fo multiple sclerosis". Member of the steering committee.
- 2009- today - **European Medicines Agency (EMA),** Amsterdam, The Netherlands; Scientific Advisory Group – Neurology, member.
- 2014-today - **University of Florence - Magnetic Resonance Interdepartmental Center (CIRM):** Director

- 2015-2016 - **Agenzia Italiana del Farmaco (AIFA) national Registry on Natalizumab, scientific committee:** member
- 2016-2020 - **European Academy of Neurology - Scientific Panel on Neuroimmunology:** co-chairman
- 2016-2018 - **Italian Society of Neurology** (Società Italiana Neurologia; SIN), Tuscan regional section: coordinator.
- 2020-today - **Italian College of the Professors of Neurology:** Steering Committee member.
- 2018-2020 - **University of Florence College of Discipline:** member
- 2018-today - **University of Florence/Careggi University Hospital Conflict of Interest Evaluation Committee:** member
- 2020-today - **University of Florence Academic Senate: Biomedical Area representative.**
- 2021-today - **Italian Society of Neurology** (Società Italiana Neurologia; SIN), Study Group on Neuroimmunology
- 2021-today - **European Academy of Neurology - Scientific Panel on Neuroimmunology:** delegate of the Italian Society of Neurology

Teaching activity: University of Florence

Year	Teaching Courses	Subject
- 1995-today,	School of Health Sciences, Medicine and Surgery program	Clinical Neurology;
- 1995-today	School of Health Sciences	Thesis tutorship: n.= 50
- 2005-today,	School of Health Sciences, Dentistry program	Clinical Neurology;
- 2005-2018,	School of Health Sciences, Nursery Sciences program.	Clinical Neurology;
- 2005-2009,	School of Psychology, Experimental Psychology program	Clinical Neurology
- 1995-today,	Resident program in Neurology.	Clinical Neurology;
- 2005-2012,	Resident program in Neuro-physio-pathology	Clinical Neurology;
- 2009-today,	Resident program in Emergency Medicine:	Clinical Neurology;
- 2012-today	Resident program in Neurosurgery	Clinical Neurology;
- 2015-today	Resident program in Psychiatry	Clinical Neurology;
- 2018-today	Resident program in Ophthalmology	Clinical neurology
- 1995-today	PhD program in Neurosciences,	Thesis tutorship: n= 24

SCIENTIFIC SOCIETY AFFILIATION

- Italian Society of Neurology (Società Italiana di Neurologia; SIN).
- European Academy of Neurology
- Italian Association of Neuroimmunology (Associazione Italiana di Neuroimmunologia; AINI)
- International Society of Neuroimmunology.

REVIEWER FOR:

Journal of Neuroimmunology, Journal Clinical Neurology and Neurosurgery, Neuroscience letters; Journal of Immunology, Neurological Sciences, Plos Medicine, Plos Pathology, Plos One, Journal of Neurological Sciences, Neuroepidemiology, Intl. MS journal. Frontiers in Neurology, Frontiers in Immunology.

Italian Multiple Sclerosis Foundation, Dutch Multiple Sclerosis Society, Singapore Medical Research Council, Italian Ministry of University and Research, National Institute of Neurological Disorders and Stroke (NIH)

EDITORIAL BOARD MEMBER:

Past: - Multiple Sclerosis International; - Multiple Sclerosis and Neuroimmunology;
Current: - Neuronal Circuits

PUBLICATIONS

Publications on international Journal quoted in "PubMed", National Library of Medicine (USA).

Full Papers

1. Raimondi L., Banchelli Soldaini G., Buffoni F., Ignesti G., **Massacesi L.**, Amaducci L. and Friedmann C.A. (1982). Rhein and derivatives. In vitro studies on their capacity to inhibit certain proteases. *Pharmacol. Res. Comm.*, 14(2): 103-112.
2. Smith M.E., Somera F.P., Saldivar R., **Massacesi L.** and Trotter J. (1984). DNA changes in spinal cords of rats with experimental allergic encephalomyelitis. *J. Neurochem.*, 43: 1635-1641.
3. **Massacesi L.**, Abbamondi A.L., Sarlo F. and Amaducci L. (1987). The control of experimental allergic encephalomyelitis with retinoic acid. Further studies. *Riv. Neurol.* 57:166-169.
4. **Massacesi L.**, Abbamondi A.L., Giorgi C., Sarlo F., Lolli F. and Amaducci L. (1987). Suppression of experimental allergic encephalomyelitis by retinoic acid. *J. Neurol. Sciences*, 80:55-64.
5. **Massacesi L.**, Abbamondi A.L., Raimondi L., Giorgi C. and Amaducci L. (1988). Lysosomal enzymes in experimental allergic encephalomyelitis: time course and evidence of the source. *Neurochem. Res.*, 13:165-169.
6. Theoharides TC, Lambrachthall M, **Massacesi L.**, et al. (1990). Reduced incidence of experimental allergic encephalomyelitis (EAE) with the tricyclic sep-ch. *Europ. J. Pharmacol.*, 183: 626-627.
7. **Massacesi L.**, Castigli E., Vergelli M., Olivotto J., Abbamondi A.L., Sarlo F. and Amaducci L. (1991). Immunosuppressive activity of 13-cis retinoic acid and prevention of experimental autoimmune encephalomyelitis in rats. *J.Clin.Invest.*, 88:1331-1337.
8. Riskind P., **Massacesi L.**, Doolittle T.H. and Hauser S.L. (1991).The role of prolactin in autoimmune demyelination: suppression of experimental allergic encephalomyelitis by bromocriptine. *Ann. Neurol.*, 29: 542-547.
9. Zehetbauer B., **Massacesi L.**, Liuzzi G. M., Vergelli M., Olivotto J., Grassi L., Riccio P. and Amaducci L. (1991). Myelin Basic Protein in lipid-bound form induces experimental allergic encephalomyelitis and demyelination in Lewis rat. *Acta Neurologica* 13: 121-132.
10. **Massacesi L.**, Parritz D., Joshi N, Letvin N. and Hauser S.L.(1992). Experimental allergic encephalomyelitis in Cynomolgus Monkeys: quantitation of T-cell responses in peripheral blood. *J.Clin. Invest.*, 90: 399-404.
11. Salvetti M and **Massacesi L.** (1992). Experimental allergic encephalomyelitis and multiple sclerosis: immunoregulatory mechanisms and T cell repertoires. *Cell. Immunol.*, 142: 217-219.
12. Salvetti M., Buttinelli C., **Massacesi L.** and Wekerle H. (1993). New approaches to the study of T-cell autoimmunity in multiple sclerosis. *J. Neuroimmunol.*, 47: 203-205.
13. Yu J.S., Pandey J. P., **Massacesi L.**, Lincoln R., Usuku K., Seboun E. and Hauser S.L. (1993). Segregation of Immunoglobulin heavy Chain constant region genes in Multiple sclerosis sibling pairs. *J. Neuroimmunol.*, 42: 113-116.
14. Lolli F., Liuzzi G.M., Vergelli M., **Massacesi L.**, Ballerini C., Amaducci L. and Riccio P. (1993). Antibodies specific for the lipid-bound form of myelin basic protein during experimental autoimmune encephalomyelitis. *J. Neuroimmunol.*, 44: 69-75
15. **Massacesi L.**, Vergelli M., Zehetbauer B., Liuzzi G.M., Olivotto J., Ballerini C., Uccelli A., Mancardi L., Riccio P. and Amaducci L. (1993). Induction of experimental autoimmune encephalomyelitis in rats and immune response to myelin basic protein in lipid bound form. *J. Neurol. Sciences*, 119: 91-98.
16. Da Vico S., **Massacesi L.**, Amaducci L. (1993). Survey of the italian neurological output in the three years 1989-1991. *It J. Neurol. Sci.*, 14: 595-598.
17. Genain C.P., Parritz D., Hoa Nguyen M., **Massacesi L.**, Ioshi N., Ferrante R., Hoffman K., Moseley M., Letvin N., Hauser S. (1994). In healthy primates, circulating autoreactive T-cells mediate autoimmune disease. *J. Clin. Invest.*, 94: 1339-1345.
18. Vergelli M., Mazzanti B., Ballerini C., Gran B., Amaducci L. and **Massacesi L.** (1995). Transforming growth factor-beta1 inhibits the proliferation of rat astrocytes induced by serum and growth factors. *J. Neurosc. Res.*, 40: 127-133.
19. **Massacesi L.**, Genain C.P., Parritz D.L., Canfield D., Letvin N. and Hauser S.L. (1995). Active and passively induced experimental autoimmune encephalomyelitis in common marmosets: a new model for multiple sclerosis. *Ann. Neurol.*, 37: 519-530.
20. Hohlfeld R., Londei M., Massacesi L. and Salvetti M. (1995).T-cell autoimmunity in multiple sclerosis. *Immunology Today (now Trends in Immunology)*, 16:259-261.
21. Amato M.P., **Massacesi L.** and Amaducci L. (1996). Clinical outcome measurements in Multiple Sclerosis trials. *MS Forum. Int. MS Journal* 3 n(1) : 19-27.
22. Vergelli M., Olivotto J., Castigli E., Gran B., Raimondi L., Pirisino R., Amaducci L. and **Massacesi L.** (1997). Immunosuppressive activity of 13-cis-retinoic acid in rats: Aspects of pharmacokinetics and pharmacodynamics. *Immunopharmacol.*, 37: 191-197.
23. Mazzanti B. , M. Vergelli, P. Riccio, R. Martin, H.F. McFarland, G.M. Liuzzi, L. Amaducci and **Massacesi L.** (1998). T cell response to Myelin Basic Protein in patients with Multiple Sclerosis and healthy donors. *J. Neuroimmunol.*, 82:

- 96-100.
24. Gran B., Gestri D., Sottini A., Quiròs Roldàn E., Bettinardi A., Signorini S., Primi D., Ballerini C., Taiuti R., Amaducci L. and **Massacesi L.** (1998). Detection of skewed T-cell receptor V-beta gene usage in the peripheral blood of patients with multiple sclerosis. *J. Neuroimmunol.*, 85: 22-32.
 25. Cascino I., Ballerini C., Audino S., Rombolà G., **Massacesi L.**, Colombo G., Scorza Smeraldi R., D'Alfonso S., Momigliano Richiardi P., Tosi R., Ruberti G. (1998). Fas Gene Polymorphisms are not associated with Systemic Lupus Erythematosus, Multiple Sclerosis and HIV Infection. *Disease Markers*, 13: 221-225.
 26. Laman J.D., van Meurs M., Schellekens M.M., de Boer M., Melchers B., **Massacesi L.**, Lassmann H., Klaassen E., 't Hart B. (1998). Expression of accessory molecules and cytokines in acute EAE in marmoset monkeys (*Callithrix jacchus*). *J. Neuroimmunol.*, 86: 30-45.
 27. 't Hart B., Bauer J., Muller H.J., Melchers B., Nicolay K., Brok H., Bontrop R., Lassmann H. and **Massacesi L.** (1998) Histopathological characterization of magnetic resonance imaging-decectable brain white matter lesions in a primate model of multiple sclerosis. *Am. J. Pathol.*, 153: 649-663.
 28. Kappos, L; Polman, C; Pozzilli, C et al (1998). Placebo-controlled multicentre randomised trial of Interferon beta-1b in treatment of secondary progressive multiple sclerosis. *Lancet*, 352: 1491-97.
 29. Mazzucco S., Nardi E., Chelli M., Ginanneschi M., Rapi G., Papini A.M., Vergelli M., Mazzanti B., **Massacesi L.**, Amaducci L. (1999). Synthesis of lipopeptides of the immunodominant epitope hMBP(83-99) containing amide or C-C bond linked hydrophobic chains for the study of T cell response. *Letters in Peptide Sciences* 6: 51-59.
 30. Mazzucco S., Matà S., Vergelli M., Fioresi R., Nardi E., Mazzanti B., Chelli M., Lolli F., Ginanneschi M., Pinto F., **Massacesi L.** and Papini A.M. (1999). A synthetic glycopeptide of human myelin oligodendrocyte glycoprotein to detect antibody responses in multiple sclerosis and other neurological diseases. *Bioorg. Med. Chem. Lett.* : 167-172.
 31. Sabbadini M.G., Manfredi AA., Bozzolo E., Ferrario L., Rugarli C., Scorza R., Origgi L., Vanoli M., Gambini O., Vanzulli L., Croce D., Campana A., Messa C., Fazio F., Tincani A., Anzola G., Cattaneo R., Padovani A., Gasparotti R., Gerli R., Quartesan R., Piccirilli M., Farsi A., Emmi E., Domeneghetti M., Piccini C., **Massacesi L.**, Pupi A., De Cristoforis M., Danieli M., Candela M., Fraticelli P., Bartolini M., Savolini U., Danieli G. and Passaleva A. (1999). Central Nervous system involvement in Systemic Lupus Eritematosus patients without overt neuropsychiatric manifestations. *Lupus* 8: 11-19.
 32. D'Alfonso S., Nisticò L., Zavattari P., Marrosu M., Murru R., Lai M., **Massacesi L.**, Ballerini C., Gestri D., Salvetti M., Ristori G., Bompreszi R., Trojano M., Liguori M., Gambi D., Quattrone A., Fruci D., Cucca F., Momigliano Richiardi P. and Tosi R. (1999). A linkage analysis of Multiple Sclerosis with candidate region markers in Sardinian and Continental Italian families. *Eur. J Hum.Gen.* 7 : 377-385.
 33. Miller D.H., Molyneux P.D., Barker G.J., Mac Manus D.G., Moseley I.F., Wagner K., and the **European Study Group on Interferon-Beta1b in Secondary Progressive Multiple Sclerosis.** (1999) Effect of Interferon-Beta1b on Magnetic Resonance Imaging Outcomes in Secondary Progressive Multiple Sclerosis: Results of a European Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial. *Ann. Neurol.*, vol. 46, 850-859.
 34. Ballerini C. Nacmias B., Rombolà G., Marcon G., **Massacesi L.**, Sorbi S. (1999) HLA A2 Allele Is Associated with Age at Onset of Alzheimer's Disease. *Ann. Neurol.*, vol. 45: 397-400.
 35. Mazzanti B., Hemmer B., Traggiai E., Ballerini C., McFarland H.F., **Massacesi L.**, Martin R. and Vergelli M. (2000). Decrypting the Spectrum of Antigen-Specific T-Cell Responses: The Avidity Repertoire of MBP-Specific T-Cells. *J. Neurosci. Res.*, 59:86-93.
 36. 't Hart B.A., van Meurs M., Brok H.P.M., **Massacesi L.**, Bauer J., Boon L., Bontrop R.E and Laman J.D. (2000). A new primate model for multiple sclerosis in the common marmoset. *Immunology Today (ora Trends in Immunology)*, 21: 290-297.
 37. Pupi A., Sestini S., De Cristofaro M.T., Emmi L., Marchione T., Salvati G., Li Gobbi F., **Massacesi L.**, Meldolesi U. (2000). Use of technetium-99mhexamethylpropyleneamine oxime single-photon emission tomography for the study of cerebral blood flow reactivity after acetazolamide infusion in patients with Behcet's disease. *Eur. J. Nucl. Med.* 27(6): 700-706.
 38. D'Alfonso S., Nisticò L., Bocchio D., Bompreszi R., Marrosu M.G., Murru M.R., Lai M., **Massacesi L.**, Ballerini C., Repice A., Solvetti M., Montesperelli C., Ristori G., Trojano M., Liguori M., Gambi D., Quattrone A., Tosi R., Momigliano-Richiardi P. (2000). An attempt of identifying MS-associated loci as a follow-up of a genomic linkage study in the Italian population. *J. Neurovirol.* 6 (S 2):18-22.
 39. Molyneux P.D., Kappos L., Polman C., Pozzilli C., Barkhof F., Filippi M., Yousry T., Hahn D., Wagner K., Ghazi M., Beckmann K., Dalhke F., Losseff N., Barker G.J., Thompson A.J., Miller D.H. and the **European Study Group on Interferon beta-1b in Secondary Progressive Multiple Sclerosis** (2000). The effect of interferon beta-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple Sclerosis. *Brain* 123: 2256-2263.
 40. Ballerini C., Campani D., Rombolà G., Gran B., Nacmias B., Amato M.P., Siracusa G., Bartolozzi L., Sorbi S. and **Massacesi L.** (2000). Association of apolipoprotein E polymorphism to clinical heterogeneity of multiple sclerosis. *Neurosci. Lett.* 296: 174-176.
 41. Papini AM, Mulinacci B, Carotenuto A, Bonetti B, Sabatino G, Peron E, Nuti F, Alcaro MC Pozo-Carrero MC, Mazzanti, B, Pazzagli m, Massacesi L, Battistini L, Chelli, M, Rovero, P, Lolli, F, Chorev M, Sawyer, TK, 2001. MS PepKit: The first diagnostic test to follow-up multiple sclerosis. *Peptide Revolution: Genomics, Proteomics & Therapeutics*
 42. Chiarugi A., Cozzi A., Ballerini C., Massacesi L. and Moroni F. (2001). Kynurenine 3-monoxygenase activity and neurotoxic kynurenine metabolites increase in the spinal cord of rats with experimental allergic encephalomyelitis. *Neuroscience* 102: 687 - 695.

43. Mancardi G., t'Hart B., Roccatagliata L., Brok H., Giunti D., Bontrop R., **Massacesi L.**, Capello E. and Uccelli A. (2001.) Demyelination and axonal damage in a non-human primate model of multiple sclerosis. *J. Neurol. Sciences* 184: 41-49.
44. Gestri D., Baldacci L., Taiuti R., Galli E., Maggi E., Piccinni M.P., Vergelli M. and **Massacesi L.** (2001). Oligoclonal T-cell repertoire in cerebrospinal fluid of patients with nervous system inflammatory diseases. *J. Neurol. Neurosurg. Psych.* 70: 767- 772.
45. Broadley S., Sawcer S., D'Alfonso S., Henseik A., Coraddu F., Gray J., Roxburgh R., Clayton D., Buttinelli C., Quattrone A, Trojano M., Momigliano Richiardi P. , **Massacesi L.** and Compston A. (2001). A genome screen for multiple sclerosis in Italian families. *Genes Immun.* 2: 205-10.
46. Mancardi G.L., Saccardi, R., Filippi, M., Gualandi F., Murialdo A., Inglese M., Marrosu M.G., Meucci G., **Massacesi L.**, Lugaresi A., Pagliai F., Sormani M.P., Sardanelli F., Marmont A. and the Italian Gitmo-Neuro Intergroup on Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis (2001). Autologous hematopoietic stem cell transplantation suppresses Gadolinium-enhanced MRI activity in multiple sclerosis. *Neurology* 57:62-68.
47. Papini A.M., Mazzanti B., Nardi E., Traggiai E., Ballerini C., Biagioli T., Kalbacher H., Beck H., Deeg M., Chelli M., Ginanneschi M., **Massacesi L.**, Vergelli M. (2001). Palmitoyl Derivatives of GpMBP Epitopes: T-Cell Response and Peptidases Susceptibility. *J. Med. Chem* 44: 3504- 3510.
48. Soldan S. S., Fogdell-Hahn A., Brennan M. B., Mittleman B. B., Ballerini C., **Massacesi L.**, Seya T., McFarland H. F. and Jacobson S. (2001). Elevated serum and CSF levels of soluble HHV-6 cellular receptor, membrane cofactor protein (MCP; CD46), in patients with multiple sclerosis. *Ann. Neurol.* 50: 486-93.
49. Vergelli M., B. Mazzanti, E. Traggiai, T. Biagioli, C. Ballerini, A Parigi, G. Pellicanò, A. Konze, **Massacesi L.** (2001). Short-term evolution of autoreactive T-cell repertoire in multiple sclerosis. *J Neurosci Res.* 66:517-24.
50. Traggiai E., Biagioli T., Rosati E., Ballerini C., Mazzanti B., Ben Nun A., **Massacesi L.**, Vergelli M. (2001). IL-7-enhanced T-cell response to myelin proteins in multiple sclerosis. *J. Neuroimmunol.* 121:111-9.
51. Kappos L., Polman C., Pozzilli C., Thompson A., Beckmann K., Dalhke F., and **the European Study Group on Interferon beta-1b in Secondary Progressive Multiple Sclerosis** (2001). Final analysis of the European multicenter trial on IFNbeta-1b secondary progressive Multiple Sclerosis. *Neurology* 57: 1969-1975.
52. Freeman J, Thompson A., Fitzpatrick R., Hutchinson M., Miltenburger C., Beckmann K., Kappos L., Dalhke F., Polman C., Pozzilli C., and **the European Study Group on Interferon beta-1b in Secondary Progressive Multiple Sclerosis** (2001). IFNbeta-1b in the treatment of secondary progressive Multiple Sclerosis. Impact on quality of life. *Neurology* 57: 1870-1875.
53. Molyneux PD, Barker GJ, Barkhof F, Beckmann K, Dahlke F, Filippi M, Ghazi M, Hahn D, MacManus D, Polman C, Pozzilli C, Kappos L, Thompson AJ, Wagner K, Yousry T, Miller DH; **European Study Group on Interferon Beta-1b in Secondary Progressive MS** (2001). Clinical-MRI correlations in a European trial of interferon beta-1b in secondary progressive MS. *Neurology* 57: 2191-7.
54. D'Alfonso S., Mellai M., Giordano M., Pastore A., Malferrari G., Naldi P., Repice A., Liguori M., Cannoni S., Milanese C., Caputo D., Savettieri G., Momigliano-Richiardi P. and the **Italian Group for the Study of Multiple Sclerosis Genetics**(2002). Identification of single nucleotide variations in the coding and regulatory regions of the myelin-associated glycoprotein gene (MAG) and study of their association with multiple sclerosis. *J. Neuroimmunol.* 126 : 196-204.
55. Muraro, P.A., Bonanni, L., Mazzanti B., Pantalone, A., Traggiai, E., **Massacesi L.**, Vergelli, M., Gambi, D. (2002). Short-term dynamics of circulating T cell receptor V beta repertoire in relapsing-remitting MS. *J. Neuroimmunol.* 127: 149-59.
56. **Massacesi L.** (2002). Compartmentalization of the immune response in the central nervous system and natural history of multiple sclerosis. Implications for therapy. *Clin Neurol Neurosurg* 104: 177-81.
57. Ballerini C., Rosati E., Salvetti M., Ristori G., Cannoni S., Biagioli T., **Massacesi L.**, Sorbi S., Vergelli M. (2002). PTPRC exon 4 gene mutation distribution in a Italian MS population. *Neuroscience Letters* 328: 325-7.
58. Buzzetti R., Pozzilli P., Di Mario U., Ballerini C., and **Massacesi L.** (2002). Multiple sclerosis and Type I diabetes. *Diabetologia* 45: 1735-6.
59. Mellai M., Giordano M., D'Alfonso S., Marchini M., Scorza R., Danieli M.G., Leone M., Ferro I., Liguori M., Trojano M., Ballerini C., **Massacesi L.**, Cannoni S., Bomprezzi R., Momigliano-Richiardi P. (2003). Prolactin and prolactin receptor gene polymorphisms in multiple sclerosis and systemic lupus erythematosus. *Human Immunol.* 64: 274-284.
60. Polman C, Kappos L, White R, Dahlke F, Beckmann K, Pozzilli C, Thompson A, Petkau J, Miller D; **European Study Group in Interferon Beta-1b in Secondary Progressive MS** (2003). Neutralizing antibodies during treatment of secondary progressive MS with interferon beta-1b. *Neurology* 60: 37-43.
61. Sormani MP, Bruzzi P, Beckmann K, Wagner K, Miller DH, Kappos L, Filippi M; **European Study Group on Interferon Beta-1b in Secondary Progressive MS** (2003). MRI metrics as surrogate endpoints for EDSS progression in SPMS patients treated with IFN beta-1b. *Neurology* 60: 1462-6.
62. Alizadeh M, Babron MC, Birebent B, Matsuda F, Quelvennec E, Liblau R, Cournu-Rebeix I, Momigliano-Richiardi P, Sequeiros J, Yaouanq J, Genin E, Vasilescu A, Bougerie H, Trojano M, Martins Silva B, Maciel P, Clerget-Darpoux F, Clanet M, Edan G, Fontaine B, Semana G. (2003) and the Portuguese and **Italian Group for MS genetics**. Genetic interaction of CTLA-4 with HLA-DR15 in multiple sclerosis patients. *Ann Neurol.* 54:119-22.
63. Akesson E, Coraddu F, Marrosu MG, **Massacesi L.**, Hensiek A, Harbo HF, Oturai A, Trojano M, Momigliano-Richiardi

- P, Cocco E, Murru R, Hillert J, Compston A and Sawcer S (2003). Refining the linkage analysis on chromosome 10 in 449 sib-pairs with multiple sclerosis. *J Neuroimmunol.* 143: 31- 38.
64. Liguori M, Sawcer S, Setakis E, Compston A, Giordano M, D'Alfonso S, Mellai M, Malferrari G, Trojano M, Livrea P, De Robertis F, **Massacesi L**, Repice A, Ballerini C, Biagioli T, Bomprezzi R, Cannoni S, Ristori G, Salvetti M, Grimaldi LM, Bionno I, Comi G, Leone M, Ferro I, Naldi P, Milanese C, Gellera C, Loredana LM, Savettieri G, Salemi G, Aridon P, Caputo D, Rosa Guerini F, Ferrante P, and Momigliano-Richiardi P (2003). A whole genome screen for linkage disequilibrium in multiple sclerosis performed in a continental Italian population. *J Neuroimmunol.* 143: 97-100.
 65. Ballerini C, Guerini F, Rombolà G, Rosati E, **Massacesi L**, Ferrante P, Caputo D, Figà Talamanca L, Naldi P, Liguori M, Alizadeh M, Momigliano-Richiardi P, D'Alfonso S (2004). HLA-Multiple Sclerosis association in Continental Italy and correlation with disease prevalence in Europe. *J Neuroimmunol.* 150:178 -85.
 66. Inglese M, G L Mancardi, E Pagani, M A Rocca, A Murialdo, R Saccardi, G Comi and M Filippi the **Italian GITMO-NEURO Intergroup on Autologous Hemotopoietic Stem Cell Transplantation** (2004). Brain tissue loss occurs after suppression of enhancement in patients with multiple sclerosis treated with autologous haematopoietic stem cell transplantation. *J. Neurol. Neurosurg. Psych.* 75: 643-644.
 67. Saccardi R, Mancardi GL, Solari A, Bosi A, Bruzzi P, Di Bartolomeo P, Donelli A, Filippi M, Guerrasio A, Gualandi F, La Nasa G, Murialdo A, Pagliai F, Papineschi F, Scappini B, Marmont AM. and the **Italian GITMO-NEURO Intergroup on Autologous Hemotopoietic Stem Cell Transplantation** (2005). Autologous HSCT for severe progressive multiple sclerosis in a multicenter trial: impact on disease activity and quality of life. *Blood.* 105:2601-7.
 68. Mazzanti B, Biagioli T., Aldinucci A., Cavaletti G., Cavaletti E., Crippa L., Oggioni N., Sala F., Sala V., Frigo M., Rota S., Tagliabue E., Ballerini C., **Massacesi L**, Riccio P. and Lolli F. (2005). Effects of Pixantrone on T- and B-cell function in the course of acute rat experimental allergic encephalomyelitis. *J. Neuroimmunol.* 168: 111-117.
 69. Capello E, Saccardi R, Murialdo A, Gualandi F, Pagliai F, Bacigalupo A, Marmont A, Uccelli A, Inglese M, Bruzzi P, Sormani MP, Cocco E, Meucci G, **Massacesi L**, Bertolotto A, Lugaresi A, Merelli E, Solari A, Filippi M, Mancardi GL; Italian GITMO-Neuro Intergroup on ASCT for Multiple Sclerosis (2005). Intense immunosuppression followed by autologous stem cell transplantation in severe multiple sclerosis. *Neurol Sci.* 26: S200-3.
 70. **Massacesi L**, Parigi A, Barilaro A, Repice AM, Pellicanò G, Konze A, Siracusa GF, Taiuti R and Amaducci L. (2005). Efficacy of Azathioprine on Multiple Sclerosis new brain lesions evaluated by Magnetic Resonance Imaging. *Arch.Neurol.*;62:1843-1847
 71. Ristori G, Cannoni S, Stazi MA, Vanacore N, Cotichini R, Alfo M, Pugliatti M, Sotgiu S, Solaro C, Bomprezzi R, Di Giovanni S, Figa Talamanca L, Nistico L, Fagnani C, Neale MC, Cascino I, Giorgi G, Battaglia MA, Buttinelli C, Tosi R, Salvetti M. and the **Italian MS genetic collaborative group** (2006). Multiple sclerosis in twins from continental Italy and Sardinia: A nationwide study. *Ann Neurol.* 59(1):27-34.
 72. The GAMES Collaborative Group, Ban M, Booth D, Heard R, Stewart G, Goris A, Vandenbroeck K, Dubois B, Laaksonen M, Ilonen J, Alizadeh M, Edan G, Babron MC, Brassat D, Clanet M, Cournu-Rebeix I, Fontaine B, Semana G, Goedde R, Epplen J, Weber A, Infante-Duarte C, Zipp F, Rajda C, Bencsik K, Vécsei L, Heggarty S, Graham C, Hawkins S, Liguori M, Momigliano-Richiardi P, Caputo D, Grimaldi LM, Leone M, **Massacesi L**, Milanese C, Salvetti M, Savettieri G, Trojano M, Bielecki B, Mycko MP, Selmaj K, Santos M, Maciel P, Pereira C, Silva A, Silva BM, Coraddu F, Marrosu MG, Akesson E, Hillert J, Datta P, Oturai A, Harbo HF, Spurkland A, Goertsches R, Villoslada P, Eraksoy M, Hensiek A, Compston A, Setakis E, Gray J, Yeo TW, Sawcer S. (2006). Linkage disequilibrium screening for multiple sclerosis implicates *JAG1* and *POU2AF1* as susceptibility genes in Europeans. *J. Neuroimmunol.* 179: 108-116.
 73. Saccardi R, Kozak T, Bocelli-Tyndall C, Fassas A, Kazis A, Havrdova E, Carreras E, Saiz A, Löwenberg B, te Boekhorst P, Gualandi F, Openshaw H, Longo G, Pagliai F, **Massacesi L**, Deconink E, Ouyang J, Zuazu Nagore F, Besalduch J, Lisukov I, Bonini A, Merelli E, Slavin S, Gratwohl A, Passweg J, Tyndall A, Steck A, Andolina M, Capobianco M, Diez Martin J, Lugaresi A, Meucci G, Sáez R, Clark R, Fernandez M, Fouillard L, Herstenstein B, Koza V, Cocco E, Baurmann H and Mancardi G on behalf of the Autoimmune Disease Working Party of EBMT (2006). Autologous stem cell transplantation for progressive multiple sclerosis: update of the European group for blood and marrow transplantation auto-immune diseases working party database. *Mult. Sclerosis J* 12: 814-823.
 74. Roccatagliata L, Rocca M, Valsasina P, Bonzano L, Sormani M, Saccardi R, Mancardi G, Filippi M; for the **Italian GITMO-NEURO Intergroup on Autologous Stem Cell Transplantation**. (2007). The long-term effect of AHSCT on MRI measures of MS evolution: a five-year follow-up study. *Mult Sclerosis.* 13: 1068-70.
 75. Aldinucci A., Gerlini G., Fossati S., Cipriani G., Ballerini C., Biagioli T., Pimpinelli N., Borgognoni L., **Massacesi L**, Moroni F. and Chiarugi A. (2007). Requirement for PARP-1 activity during human dendritic cell maturation. *J. Immunol.* 179: 305-12.
 76. D'Alfonso S., Bolognesi E., Guerini F., Barizzone N., Bocca S., Castelli L., Bergamaschi L., Agliardi C., Ferrante P., Naldi P., Leone M., Caputo D., Ballerini C., Salvetti M., Galimberti D., **Massacesi L**, Trojano M., Momigliano-Richiardi P. (2008). A sequence variation in the MOG gene is involved in Multiple Sclerosis susceptibility in Italy. *Genes and Immun* 9: 7-15.
 77. Luccarini I., Ballerini C., Biagioli T., Biamonte F., Bellucci A., Rosi M.C., Grossi C., **Massacesi L**. and Casamenti F. (2008). Combined treatment with atorvastatin and minocycline suppresses severity of EAE. *Exp. Neurol.*, 211: 214.
 78. Mazzanti B., Aldinucci A., Biagioli T., Barilaro A., Urbani S., Dal Pozzo S., Amato MP, Siracusa GF., Crescioli C., Manuelli A., Bosi A., Saccardi R., **Massacesi L**. and Ballerini C. (2008). Differences in mesenchymal stem cell cytokine profiles between MS patients and healthy donors: Implication for assessment of disease activity and

- treatment. *J. Neuroimmunol.* 199:142-50.
79. Hart B. and **Massacesi L** (2009). Clinical, pathological and immunological aspects of the multiple sclerosis model in common marmosets (*Callithrix jacchus*). *J. Neuropathol. Exp. Neurol.* 68 (4): 341-355.
 80. Bizzoco E, Lolli F, Repice A, Falcini M, Taiuti R, Siracusa GF, Amato MP, Biagioli T, Lori S, Moretti M, Vinattieri A, Nencini P, **Massacesi L**, Matà S. (2009). Prevalence of Neuromyelitis Optica Spectrum Disorder and Phenotype Distribution. *J. Neurol.* 256:1891-8
 81. Aldinucci A, Biagioli T, Manuelli C, Repice A, **Massacesi L**, Ballerini C. (2010). Modulating dendritic cells (DC) from immunogenic to tolerogenic responses: a novel mechanism of AZA/6-MP. *J. Neuroimmunol.* 218:28-35.
 82. Aldinucci A, Rizzetto L, Pieri L, Nosi D, Romagnoli P, Biagioli T, Mazzanti B, Saccardi R, Beltrame L, **Massacesi L**, Cavalieri D, Ballerini C (2010). Inhibition of Immune Synapse by Altered Dendritic Cell Actin Distribution: A New Pathway of Mesenchymal Stem Cell Immune Regulation. *J. Immunol.* 185:5102-10.
 83. Gaitán M, Shea C, Evangelou I, Stone R, Fenton K, Bielekova B, **Massacesi L**, Reich D. (2011). Evolution of the Blood-Brain Barrier in Newly Forming Multiple Sclerosis Lesions. *Ann. Neurol.* 70: 22-29.
 84. María I Gaitán ; Colin D Shea ; Iordanis E Evangelou ; Roger D Stone ; Kaylan M Fenton ; Bibiana Bielekova ; **Luca Massacesi** ; Daniel S Reich (2011). Reply. *Annals of neurology* , 70: 669-670.
 85. Snowden JA, Saccardi R, Allez M, Ardizzone S, Arnold R, Cervera R, Denton C, Hawkey C, Labopin M, Mancardi G, Martin R, Moore J J, Passweg J, Peters C, Rabusin M, Rovira M, van Laar JM & Farge D on behalf of the **EBMT Autoimmune Disease**, (2011). Haematopoietic stem cells transplantation (HSCT) in severe autoimmune diseases: updated guidelines of the European group for bone marrow transplantation (EBMT). *Bone marrow Transplantation*
 86. Mancardi G, Sormani M, Di Gioia M, Vuolo L, Gualandi F, Amato M, Capello E, Currò D, Uccelli A, Bertolotto A, Gasperini C, Lugaresi A, Merelli E, Meucci G, Motti L, Tola M, Scarpini E, Repice A, **Massacesi L**, Saccardi R. (2012) Autologous haematopoietic stem cell transplantation with an intermediate intensity conditioning regimen in multiple sclerosis: the Italian multi-centre experience. *Mult Scler. J.* 18: 835-842.
 87. Lutterotti A, Jelcic I, Schulze C, Schippling S, Breiden P, Mazzanti B, Reinhard S, DiGioia M, Repice A, **Massacesi L**, Sputtek A, Salinas-Riester G, Kroeger N, Sospedra M, Saccardi R, Zander A and Martin R (2012). Gene expression and epigenetic profiling of CD34+ hematopoietic progenitor cells in multiple sclerosis patients – absence of proinflammatory signatures. *Mult Scler.* .
 88. Saccardi R, Freedman MS, Sormani MP, Atkins H, Farge D, Griffith LM, Kraft G, Mancardi GL, Nash R, Pasquini M, Martin R, Muraro PA; European Blood and Marrow Transplantation Group; Center for International Blood and Marrow Research; **HSCT in MS International Study Group** (2012). A prospective, randomized, controlled trial of autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: a position paper. *Mult Scler. Jun;18(6):825-34.*
 89. Zamboni P, Bertolotto A, Boldrini P, Cenni P, D'Alessandro R, D'Amico R, Del Sette M, Galeotti R, Galimberti S, Liberati A, **Massacesi L**, Papini D, Salvi F, Simi S, Stella A, Tesio L, Valsecchi MG, Filippini G. (2012). Efficacy and safety of venous angioplasty of the extracranial veins for multiple sclerosis. Brave Dreams Study (Brain Venous Drainage Exploited Against Multiple Sclerosis): study protocol for a randomized controlled trial. *Trials* 13: 183-196.
 90. Carrai V, Donnini I, Mazzanti B, Alterini R, Amato MP, Barilaro A, Bosi A, **Massacesi L**, Portaccio E, Repice AM, Rotunno G and Saccardi R. (2013). Immunohistochemistry analysis of bone marrow biopsies in multiple sclerosis patients undergoing autologous hematopoietic stem cells transplantation. *Clin. Neurol. and Neurosurg.* 115: 1044 – 1048
 91. Aldinucci A, Turco A, Biagioli T, Toma F, Bani D, Guasti D, Manuelli C, Rizzetto L, Cavalieri D, **Massacesi L**, Mello T, Scaini D, Bianco A, Ballerini L, Prato M, Ballerini C (2013). Carbon nanotube scaffolds instruct human dendritic cells: modulating immune responses by contacts at the nanoscale. *Nano Letters* 13(12):6098-105.
 92. Paganini M, Biggeri A, Romoli AM, Mechi C, Ghelli E, Berti V, Pradella S, Bucciantini S, Catelan D, Saccardi R, Lombardini L, Mascalchi M, **Massacesi L**, Porfirio B, Di Lorenzo N, Vannelli GB, Gallina P (2014). Foetal striatal grafting slows motor and cognitive decline of Huntington's disease. *J. Neurol. Neurosurg. Psychiatr.* 85: 974-981.
 93. Mascalchi M, Ginestroni A, Toschi N, Poggesi A, Cecchi P, Salvadori E, Tessa C, Cosottini M, De Stefano N, Pracucci G, Pantoni L, Inzitari D, Diciotti S and **VMCI Tuscany investigators**. (2014). The burden of microstructural damage modulates cortical activation in elderly subjects with MCI and leuko-araiosis. A DTI and fMRI study. *Human Brain Mapping* 35: 819–830.
 94. Gaitan M, Maggi P, Wohler N, Leibowitch M, Sati P, Calandri B, Merkle L, **Massacesi L**, Silva A, Jacobson S, Rech D. (2014) Perivenular Brain lesions in a primate multiple sclerosis model at 7-tesla MRI. *Mult. Scler.* 20(1):64–71.
 95. Maggi P, Cummings Macri S, Gaitán M, Leibovitch E, Wohler J, Knight H, Ellis M, Wu T, Silva A, **Massacesi L**, Jacobson S, Westmoreland S, Reich D (2014). The formation of inflammatory demyelinated lesions in cerebral white matter. *Ann. Neurol.* 76:594-608.
 96. **Massacesi L**, Tramacere I, Amoroso S, Battaglia M, Benedetti MD, Filippini G, La Mantia L, Repice A M, Solari A, Tedeschi G, Milanese C (2014). Azathioprine versus Beta Interferons for relapsing-remitting multiple sclerosis: a multicentre randomized non-inferiority trial. *PlosOne*, 9(11):e113371; e-Pub, November 17 2014.
 97. Bonechi E, Aldinucci A, Mazzanti B., DiGioia M, Repice A, Manuelli C, Saccardi R, **Massacesi L**, Ballerini C, (2014). Increased CXCL10 expression in Multiple Sclerosis MSCs and monocytes is unaffected by AHST. *Ann Clin Transl Neurol.* 1:650-8.
 98. Laroni A, Brogi D, Morra VB, Guidi L, Pozzilli C, Comi G, Lugaresi A, Turrini R, Raimondi D, Uccelli A, Mancardi GL, **EAP Investigators** (2014). Safety of the first dose of fingolimod for multiple sclerosis: results of an open-label clinical trial. *BMC Neurol.* 14:65.

99. Gallina P, Paganini M, Lombardini L, Biggeri A, Marini M, Morelli AM, Bucciantini S, Sarchielli E, Ambrosini S, Mechi C, Romoli AM, Ghelli E, Pradella S, Urbani S, Mazzanti B, Berti V, Giordano GP, Campolo M, Dal Pozzo S, Piacentini S, Saccardi R, **Massacesi L**, Mascalchi M, Bosi A, Conti R, Porfirio B, Di Lorenzo N, Vannelli GB, (2014). Trapianto intracerebrale di striato fetale nella malattia di Huntington: un aggiornamento dell'esperienza clinica italiana. *Trapianti* 18: 5-11.
100. Salvadori E, Poggesi A, Valenti R, Pracucci G, Pescini F, Pasi M, Nannucci S, Marini S, Del Bene A, Ciolli L, Ginestroni A, Diciotti S, Orlandi G, Di Donato I, De Stefano N, Cosottini M, Chiti A, Federico A, Dotti MT, Bonuccelli U, Inzitari D, Pantoni L and the **VMCI-Tuscany Study Group** (2015). Development and psychometric properties of a neuropsychological battery for mild cognitive impairment with small vessel disease: the VMCI-Tuscany Study. *J Alzheimers Dis.* 43: 1313-23.
101. Maggi P, Mazzoni L, Moretti M, **Massacesi L** (2015). SWI enhances vein detection using gadolinium in multiple sclerosis. *Acta Radiologica Open.* 4:2047981614560938.
102. Clausi V, Gianneccchini S, Magnani E, Repice A, Mechi C, Martelli F, Azzi A, **Massacesi L**. (2015). Markers of JC Virus Infection in Multiple Sclerosis Patients Under Natalizumab Therapy. *Neurology Neuroimmunol Neuroinflamm.* 2: e58.
103. Mancardi GL, Sormani MP, Gualandi F, Saiz A, Carreras E, Merelli E, Donelli A, Lugaresi A, Di Bartolomeo P, Rottoli MR, Rambaldi A, Amato MP, **Massacesi L**, Di Gioia M, Vuolo V, Currò D, Roccatagliata L, Filippi M, Aguglia U, Iacopino P, Farge D, and Saccardi R. (2015). Autologous Haematopoietic Stem Cell Transplantation in Multiple Sclerosis: a phase II trial. *Neurology.* 84:981-8.
104. Giovannelli I, Martelli F, Repice AM, **Massacesi L**, Azzi A and Gianneccchini S (2015). Detection of JCPyV microRNA in Blood and urine samples of multiple sclerosis patients under natalizumab therapy. *J. of Neurovirology*, 21: 666-70.
105. Capobianco M, Lo Re M, Sangalli F, Muiola L, Perini P, Gallo P, Danni M, Provinciali L, Repice AM, **Massacesi L**, Messina S, Patti F, Laroni A, Mancardi GL, Pucci E, Calabrese M and Bertolotto A (2015). Cyclophosphamide Pulse Therapy after Natalizumab Discontinuation for Multiple Sclerosis: a multicenter study. *J Mult Scler (Foster City)* 2:151.
106. Maggi P, Sati P, **Massacesi L**. (2016). Magnetic resonance imaging of experimental autoimmune encephalomyelitis in the common marmoset. *J Neuroimmunol.* 304:86-92.
107. Lagi F, Bartalesi F, Pecile P, Biagioli T, Caldini AL, Fanelli A, Giannazzo G, Grifoni S, **Massacesi L**, Bartoloni A, Rossolini GM. (2016). Proposal for a New Score-Based Approach To Improve Efficiency of Diagnostic Laboratory Workflow for Acute Bacterial Meningitis in Adults. *J Clin Microbiol.* 54:1851-4.
108. Montanari E, Rottoli M, Maimone D, Confalonieri P, Plewnia K, Frigo M, Francia A, Pala A, Losignore NA, Ragonese P, Veneziano A; **POSIDONIA study group**. (2016). A 12-month prospective, observational study evaluating the impact of disease-modifying treatment on emotional burden in recently-diagnosed multiple sclerosis patients: The POSIDONIA study. *J Neurol Sci.* 15;364:105-9.
109. Salvadori E, Poggesi A, Valenti R, Pracucci G, Pescini F, Pasi M, Nannucci S, Marini S, Del Bene A, Ciolli L, Ginestroni A, Diciotti S, Orlandi G, Di Donato I, De Stefano N, Cosottini M, Chiti A, Federico A, Dotti MT, Bonuccelli U, Inzitari D, Pantoni L; **VMCI-Tuscany Study Group** (2016). Operationalizing mild cognitive impairment criteria in small vessel disease: the VMCI-Tuscany Study. *Alzheimers Dement.* 2016 Apr;12(4):407-18.
110. Sati P, Oh J, Constable RT, Evangelou N, Guttman CR, Henry RG, Klawiter EC, Mainero C, **Massacesi L**, McFarland H, Nelson F, Ontaneda D, Rauscher A, Rooney WD, Samaraweera AP, Shinohara RT, Sobel RA, Solomon AJ, Treaba CA, Wuerfel J, Zivadinov R, Sicotte NL, Pelletier D, Reich DS; NAIMS Cooperative (2016). The central vein sign and its clinical evaluation for the diagnosis of multiple sclerosis: a consensus statement from the North American Imaging in Multiple Sclerosis Cooperative. *Nat Rev Neurol.* 12:714-722.
111. Cadavid D, Balcer L, Galetta S, Aktas O, Ziemssen T, Vanopdenbosch L, Frederiksen J, Skeen M, Jaffe GJ, Butzkueven H, Ziemssen F, **Massacesi L**, Chai Y, Xu L, Freeman S; RENEW Study Investigators (2017). Safety and efficacy of opicinumab in acute optic neuritis (RENEW): a randomised, placebo-controlled, phase 2 trial. *Lancet Neurol.* 16:189-199.
112. Muraro P, Pasquini M, Atkins HL, Bowen JD, Farge D, Fassas A, Freedman MS, Georges GE, Gualandi F, Hamerschlag N, Havrdova E, Kimiskidis VK, Kozak T, Mancardi GL, **Massacesi L**, Moraes DA, Nash RA, Pavletic S, Ouyang J, Rovira M, Saiz A, Simoes B, Trnený M, Zhu L, Badoglio M, Zhong X, Sormani MP, Saccardi R. Multiple Sclerosis–Autologous Hematopoietic Stem Cell Transplantation (MS-AHSCT) Long-term Outcomes Study Group (2017). Long-term Outcomes After Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis. *JAMA Neurol.* 74:459-469.
113. Forci B, Mariottini A, Mechi C, **Massacesi L**, Repice A. (2017). Disease reactivation following fingolimod withdrawal in multiple sclerosis: Two case reports. *Mult Scler Relat Disord.* 2017 Jul;15:24-26.
114. Zamboni P, Tesio L, Galimberti S, **Massacesi L**, Salvi F, D'Alessandro R, Cenni P, Galeotti R, Papini D, D'Amico R, Simi S, Valsecchi MG, Filippini G and the Brave Dreams Research Group (2018). Efficacy and safety of extracranial vein angioplasty in multiple sclerosis: a randomized clinical trial. *JAMA Neurol.*, 75:35-43.
115. Maggi P, Absinta M, Grammatico M, Vuolo L, Emmi G, Carlucci G, Spagni G, Barilaro A, Repice AM, Emmi L, Prisco D, Martinelli V, Scotti R, Sadeghi N, Perrotta G, Sati P, Dachy B, Reich DS, Filippi M, **Massacesi L**. (2018). The central vein sign differentiates multiple sclerosis from CNS inflammatory vasculopathies. *Ann Neurol*, 83:283-294.
116. Kapoor R, Ho PR, Campbell N, Chang I, Deykin A, Forrestal F, Lucas N, Yu B, Arnold DL, Freedman MS, Goldman MD, Hartung HP, Havrdová EK, Jeffery D, Miller A, Sellebjerg F, Cadavid D, Mikol D, Steiner D; **ASCEND investigators** (2018) Effect of natalizumab on disease progression in secondary progressive multiple sclerosis

- (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension. *Lancet Neurol.* 17:405-415.
117. Cadavid D, Balcer L, Galetta S, Aktas O, Ziemssen T, Vanopdenbosch LJ, Leocani L, Freedman MS, Plant GT, Preinergerova JL, Ziemssen F, **Massacesi L**, Chai Y, Xu L; RENEW Study Investigators. (2018). Predictors of response to opicinumab in acute optic neuritis. *Annals of Clinical and Translational Neurology.* 15;5(10):1154-1162.
 118. D'Amore A, Tessa A, Casali C, Dotti MT, Filla A, Silvestri G, Antenora A, Astrea G, Barghigiani M, Battini R, Battisti C, Bruno I, Cereda C, Dato C, Di Iorio G, Donadio V, Felicori M, Fini N, Fiorillo C, Gallone S, Gemignani F, Gigli GL, Graziano C, Guerrini R, Gurrieri F, Kariminejad A, Lieto M, Marques Lourenço C, Malandrini A, Mandich P, Marcotullì C, Mari F, **Massacesi L**, Melone MAB, Mignarri A, Milone R, Musumeci O, Pegoraro E, Perna A, Petrucci A, Pini A, Pochiero F, Pons MR, Ricca I, Rossi S, Seri M, Stanzial F, Tinelli F, Toscano A, Valente M, Federico A, Rubegni A, Santorelli FM. (2018). Next Generation Molecular Diagnosis of Hereditary Spastic Paraplegias: An Italian Cross-Sectional Study. *Front Neurol.* 9:981.
 119. Trojano M, Bergamaschi R, Amato MP, Comi G, Ghezzi A, Lepore V, Marrosu MG, Mosconi P, Patti F, Ponzio M, Zaratin P, Battaglia MA. (2018). **Italian Multiple Sclerosis Register Centers Group**. The Italian multiple sclerosis register. *Neurol Sci.* 40(1):155-165.
 120. Mariottini A, Innocenti C, Forci B, Magnani E, Mechi C, Barilaro A, Nistri R, Fani A, Saccardi R, **Massacesi L**, Repice AM (2019). Safety and efficacy of autologous hematopoietic stem cell transplantation following natalizumab discontinuation in aggressive Multiple Sclerosis. *Eur J Neurol.* 26(4):624-630
 121. Maggi P, Absinta M, Sati P, Perrotta G, **Massacesi L**, Dachy B, Pot C, Meuli R, Reich DS, Filippi M, Pasquier RD, Théaudin M (2019). The "central vein sign" in patients with diagnostic "red flags" for multiple sclerosis: A prospective multicenter 3T study. *Mult Scler J.*
 122. Pasca M, Picchioni A, Mazzeo S, Terenzi F, Prestipino E, Fratangelo R, Repice AM, Carlucci G, **Massacesi L**, Barilaro A (2019). A Case of Recurrent Progressive Multifocal Leukoencephalopathy After Human Stem Cell Transplant, With Detection of John Cunningham Virus and Human Herpesvirus 6 on Cerebrospinal Fluid, Treated With Mirtazapine, Olanzapine and Fosfarnet. *Intractable Rare Dis Res* 8, 275-278.
 123. Gastaldi M, Mariotto S, Giannoccaro MP, Iorio R, Zoccarato M, Nosadini M, Benedetti L, Casagrande S, Di Filippo M, Valeriani M, Ricci S, Bova S, Arbasino C, Mauri M, Versino M, Vigevano F, Papetti L, Romoli M, Lapucci C, Massa F, Sartori S, Zuliani L, Barilaro A, De Gaspari P, Spagni G, Evoli A, Liguori R, Ferrari S, Marchioni E, Giometto B, **Massacesi L**, Franciotta D (2020). Subgroup Comparison According to Clinical Phenotype and Serostatus in Autoimmune Encephalitis: A Multicenter Retrospective Study. *Eur J Neurol.* 27(4):633-643.
 124. Mariottini A, Filippini S, Innocenti C, Forci B, Mechi C, Barilaro A, Fani A, Carlucci G, Saccardi R, Luca **Massacesi L**, Repice AM, 2020. Impact of autologous haematopoietic stem cell transplantation on disability and brain atrophy in secondary progressive multiple sclerosis *Mult Scler* 2020 Feb 3;
 125. Berardelli A, Silani V, Barone P, Calabresi P, Girlanda P, Lopiano L, **Massacesi L**, Monaco S, Onofri M, Tassorelli C, Tedeschi G. (2020). Neurology and the COVID-19 emergency. *Neurol Sci.* 41:1343-1344
 126. Piccini B, M, Amato MP, Bartalini S, Falcini M, Giannini M, Magnani E, **Massacesi L**, Repice AM, Vascotto M, Grosso S. (2020). Association of celiac disease in patients with multiple sclerosis in Tuscany. *Rev Esp Enferm Dig.* 112:474-476.
 127. Amoriello R, Greiff V, Aldinucci A, Bonechi E, Carnasciali A, Peruzzi B, Repice AM, Mariottini A, Saccardi R, Mazzanti B, **Massacesi L**, Ballerini C. (2020). The TCR Repertoire Reconstitution in Multiple Sclerosis: Comparing One-Shot and Continuous Immunosuppressive Therapies. *Front Immunol.* 11:559.
 128. Steingo B, Al Malik Y, Bass AD, Berkovich R, Carraro M, Fernández Ó, Ionete C, **Massacesi L**, Meuth SG, Mitsikostas DD, Pardo G, Simm RF, Traboulsee A, Choudhry Z, Daizadeh N, Compston DAS CAMMS223, CAMMS03409, and TOPAZ Investigators. (2020). Long-term efficacy and safety of alemtuzumab in patients with RRMS: 12-year follow-up of CAMMS223. *J Neurol.* Jun 24. E-pub.
 129. Berardelli A, Silani V, Barone P, Calabresi P, Girlanda P, Lopiano L, **Massacesi L**, Monaco S, Onofri M, Tassorelli C, Tedeschi G., 2020. Neurology and the COVID-19 emergency. *Neurol Sci.* 41:1343-1344.
 130. Signori A, Boffa G, Bovis F, Mariottini A, Repice AM, Inglese M, Amato MP, Mancardi GL, **Massacesi L**, Saccardi R and Sormani MP (2021). Prevalence of disability improvement as a potential outcome for multiple sclerosis trials. *Multiple Sclerosis J.*, 27:706-711.
 131. Lepore V, Bosetti C, Santucci C, Iaffaldano P, Trojano M, Mosconi P; **Italian Multiple Sclerosis Register Centers Group**, the Scientific Committee of Italian SM Register. (2021). Detection of disability worsening in relapsing-remitting multiple sclerosis patients: a real-world roving Expanded Disability Status Scale reference analysis from the Italian Multiple Sclerosis Register. *Eur J Neurol.*, 28567-578
 132. Pasca M, Forci B, Mariottini A, Mechi C, Barilaro A, **Massacesi L**, Repice AM. (2021). Sustained disease remission after discontinuation of disease-modifying treatments in relapsing-remitting multiple sclerosis. *Mult. Scler. Rel. Dis.* 47: 102591. Online ahead of print.
 133. Boffa, **Massacesi L**. Inglese M, Mariottini A, Capobianco M, Moiola L, Amato MP, Cottone S, Gualandi F, De Gobbi M, Greco R, Scime R, Frau J, Zimatore GB, Bertolotto A, Comi G, Uccelli A, Signori A, Angelucci E, Innocenti C, Ciceri F, Repice AM, Sormani MP, R. Saccardi R, Mancardi GL and the Italian BMT-MS study group. (2021). Long-Term Clinical Outcomes of Hematopoietic Stem Cell Transplantation in Multiple Sclerosis. *Neurology* (online ahead of print, January 2021).
 134. Amoriello R, Chernigovskaya M, Greiff V, Carnasciali A, **Massacesi L**, Barilaro A, Repice AM, Biagioli T, Aldinucci A,

- Muraro PA, Laplaud DA, Lossius A, Ballerini C (2021). TCR repertoire diversity in Multiple Sclerosis: High-dimensional bioinformatics analysis of sequences from brain, cerebrospinal fluid and peripheral blood. *EBioMedicine*. 2021 Jun; 68:103429. Epub 2021 Jun 11.
135. Baroncini D, Simone M, Iaffaldano P, Brescia Morra V, Lanzillo R, Filippi M, Romeo M, Patti F, Chisari CG, Cocco E, Fenu G, Salemi G, Ragonese P, Inglese M, Cellerino M, Margari L, Comi G, Zaffaroni M, Ghezzi A. (2021). Italian MS registry. Risk of Persistent Disability in Patients With Pediatric-Onset Multiple Sclerosis. *JAMA Neurol*. Jun 1;78(6):726-735.
 136. Contento M, Bertaccini B, Biggi M, Magliani M, Failli Y, Rosati E, **Massacesi L**, Paganini M. (2021). Prediction of seizure recurrence risk following discontinuation of antiepileptic drugs. *Epilepsia*. 2021 July12.
 137. Contento M, Bertaccini B, Biggi M, Magliani M, Failli Y, Rosati E, Massacesi L, Paganini M. (2021) Response: Brightening the crystal ball: A constructive reappraisal of the postwithdrawal seizure relapse prediction model. *Epilepsia*. 62(12):3148-3149.
 138. Mariottini A, Marchi L, Innocenti C, Di Cristinzi M, Pasca M, Filippini S, Barilaro A, Mechi C, Fani A, Mazzanti B, Biagioli T, Materozzi F, Saccardi R, **Massacesi L** and Repice AM (2022) Intermediate-Intensity Autologous Hematopoietic Stem Cell Transplantation Reduces Serum Neurofilament Light Chains and Brain Atrophy in Aggressive Multiple Sclerosis. *Front. Neurol*. 13:820256.
 139. Mariottini A, Bulgarini G, Forci B, Innocenti C, Mealli F, Mattei A and **Massacesi L**. (2022). Autologous hematopoietic stem cell transplantation vs low-dose immunosuppression in secondary-progressive multiple sclerosis. *European Journal of Neurology*, 29:1708-1718.
 140. Mariottini A, Bertozzi A, Marchi L, Di Cristinzi M, Mechi C, Barilaro A, **Massacesi L** and Repice AM. (2022) Effect of disease-modifying treatments on antibody-mediated response to anti- COVID19 vaccination in people with multiple sclerosis. *Journal of Neurology*, 269(6):2840-2847.
 141. Mariottini A, Forci B, Gualdani E, Romoli M, Repice AM, Barilaro A, Mechi C, **Massacesi L** and Francesconi P. (2022). Incidence of malignant neoplasms and mortality in people affected by multiple sclerosis in the epoch of disease-modifying treatments: a population-based study on Tuscan residents. *Multiple Sclerosis and Related Disorders*, 60:103679.
 142. Azzolini F, Farina A, Gastaldi M, Barilaro A, Scotti V, Falchetti G, Fainardi E, Moretti M, and **Massacesi L**. (2022). Leptomeningeal gadolinium enhancement in autoimmune GFAP-astrocytopathy. *Neurology*, 98:720-722.
 143. Mariottini A, Repice AM, Barilaro A and **Massacesi L** (2022). Anti-SARS-Cov2 vaccination at the time of the COVID-19 pandemic: suspected adverse events reporting is the milestone of post-marketing surveillance". *Neurological Sciences*, 43:4095-4097.
 144. Mariottini A, Marchi L., Innocenti C , Di Cristinzi M, Pasca M, Filippini S, Barilaro A, Mechi C, Fani A, Mazzanti B, Biagioli T, Materozzi F, Saccardi R, **Massacesi L**, Repice AM. 2022. Intermediate-Intensity Autologous Hematopoietic Stem Cell Transplantation Reduces Serum Neurofilament Light Chains and Brain Atrophy in Aggressive Multiple Sclerosis. *Front Neurol* 24:820256.
 145. Antonio Farina, Silvia Falso, Sara Cornacchini, Gregorio Spagni, Gabriele Monte, Alice Mariottini, **Luca Massacesi**, Alessandro Barilaro, Amelia Evoli, Valentina Damato. 2022. Safety and tolerability of SARS-Cov-2 vaccination in patients with myasthenia gravis: A multicenter experience. *Eur J Neurol*. 29(8):2505-2510
 146. Bergamaschi R, Beghi E, Bosetti C,, L **Massacesi**,, Maria Trojano, Mario Alberto Battaglia, Marco Capobianco, Maura Pugliatti, Monica Ulivelli, Paola Mosconi, Claudio Gasperini, Francesco Patti, Maria Pia Amato, Roberto Bergamaschi, Giancarlo Comi. 2022. Do patients' and referral centers' characteristics influence multiple sclerosis phenotypes? Results from the Italian multiple sclerosis and related disorders register. *Neurol Sci*. 2022 Jun 7.
 147. Amoriello R, Rizzo R, Mariottini A, Bortolotti D, Gentili V, Bonechi E, Aldinucci A, Carnasciali A, Peruzzi B, Repice AM, **Massacesi L**, Fainardi E, Ballerini C. (2022) Investigating Serum sHLA-G Cooperation With MRI Activity and Disease-Modifying Treatment Outcome in Relapsing-Remitting Multiple Sclerosis. *Front Neurol*.13:872396.
 148. **Massacesi L**, Mariottini A, Nicoletti F.. 2022. Relevance of Pathogenetic Mechanisms to Clinical Effectiveness of B-Cell-Depleting Monoclonal Antibodies in Multiple Sclerosis. *J. Clin Med* 1:4288-4293.
 149. Cornacchini S, Farina A, Contento M, Berti V, Biggi M, Barilaro A, **Massacesi L**, Damato V, Rosati E. 2022. Long-term-video monitoring EEG and 18F-FDG-PET are useful tools to detect residual disease activity in anti-LG11-Abs encephalitis: A case report. *Front Neurol*. 13:949240.
 150. Boffa G, Signori A, **Massacesi L.**, Mariottini A, Sbragia E, Cottone S, Amato MP, Gasperini C, Moiola L, Meletti S, Repice AM, Brescia Morra V, Salemi G, Patti F, Filippi M, De Luca G, Lus G, Zaffaroni M, Sola P , Conte A, Nistri R, Aguglia U, Granello F, Galgani S, Caniatti LM, Lugaresi A, Romano S, Iaffaldano P, Cocco E, Saccardi R, Angelucci E, Troiano M, Luigi Mancardi GL, Maria Pia Sormani MP, and Inglese M. 2022. Hematopoietic Stem Cell Transplantation In People With Active Secondary Progressive Multiple Sclerosis. *Neurology*, in press.

Book Chapters

151. Amaducci L., **Massacesi L.**, Guarnieri B.M. (1983). Neurochemical aspects of multiple sclerosis. In "New trends of multiple sclerosis research", Cazzullo C. L., Caputo C.L., Ghezzi A. eds., pp. 125-130.
152. Amaducci L., **Massacesi L.**, Guarnieri B.M., and Cambi F. (1984). Proteases, protease inhibitors and diseases of the nervous system. In "Neuroimmunology", Behan P.O. and Spreafico F. eds., pp. 127-148. Raven Press (New York). Massacesi L. and Amaducci L. (1986). Selective immunosuppression in multiple sclerosis, in "Virology and immunology in multiple sclerosis", Cazzullo C.L., Caputo D., Ghezzi A., Zaffaroni M. editors, pp. 147-152. Springer-Verlag (Berlin).
153. **Massacesi L.**, Abbamondi A.L., Castigli E., Sarlo F. and Amaducci L.(1987). Encefalomielite allergica sperimentale acido retinoico. In "La neuroimmunologia clinica oggi", Annunziata P. and Guazzi G. eds.: 47-56, Piccin (Padova).
154. **Massacesi L.**, Abbamondi A.L., Castigli E. and Amaducci L. (1988). Immunosuppression in experimental allergic encephalomyelitis. In "A multidisciplinary approach to myelin diseases", Serlupi Crescenzi G. ed. Plenum Press (New York) pp. 251-258.
155. **Massacesi L.**, Abbamondi A.L., Castigli E., Sarlo F. and Amaducci L. (1988). Immunohistochemical study of the suppressive effect of retinoic acid (RA) on experimental allergic encephalomyelitis. In "Trends in European multiple sclerosis research", Confavreux C., Aimard G. and Devic M. eds. Excerpta Medica (Amsterdam), pp. 147-152.
156. **Massacesi L.**, Abbamondi A.L., Sarlo S., Castigli E., Olivotto J., Vergelli M. and Amaducci L. (1989). Role of astroglial cells in experimental allergic encephalomyelitis. In "Trends in neuroimmunology", Marrosu M.G., Cianchetti C. and Tavolato B. eds., Plenum Press (New York), pp. 97-102.
157. **Massacesi L.**, Sarlo F., Abbamondi A.L., Castigli E., Olivotto J., Vergelli M., Raimondi L., Medica A. and Amaducci L. (1989). Immunosuppressive activity of Retinoic Acid (RA). In "Multiple Sclerosis Research", M.A. Battaglia ed., Elsevier Science Publishers B.V., pp. 215-224. advances in multiple sclerosis therapy", R.E. Gonsette, P. Delmotte, eds., Elsevier Science Publishers B.V., pp. 377-378.
158. **Massacesi L.**, Sarlo F., Castigli E., Olivotto J., Vergelli M., Abbamondi A.L. and Amaducci L. (1989). Effects of retinoic acid on passive transfer EAE. In "Recent advances in multiple sclerosis therapy", R.E. Gonsette, P. Delmotte, eds., Elsevier Science Publishers B.V., pp. 195-198.
159. Vergelli M., Sorrentino G. and **Massacesi L.** (1993). Malattie degenerative. In "Neuroimmunologia Clinica", Bruno Tavolato ed. Il Pensiero Scientifico ed. (Roma), pp. 213-228.
160. **Massacesi L.**, Amato M.P. and Amaducci L. (1994). Immunosuppression in Multiple Sclerosis: state of the art and future perspectives. In "A multidisciplinary approach to myelin diseases. II", S. Salvati ed. Plenum Press (New York), pp. 255-259.
161. Fonda C., Amato M.P., **Massacesi L.**, Falcini M. Bartolozzi L. and Amaducci L. (1995). Confronto fra RM dopo somministrazione di gadolinio, senza e dopo applicazione del "trasferimento di magnetizzazione" nella sclerosi multipla. In "Neuroradiologia", L.Bozzao editor, Centauro (Udine), pp.273-280.
162. **Massacesi L.** (1996). L'encefalomielite autoimmune sperimentale. In "Neurobiologia e Neuroimmunologia Clinica", a cura di Federico A. e Annunziata P. CIC edizioni Internazionali (Roma), pp 85-93.
163. Mazzanti B., Traggiai E., Hemmer B., Martin R., **Massacesi L.**, Vergelli M. (1999). The affinity spectrum of myelin basic protein reactive T cells. In "Advances in the immunopathogenesis of multiple sclerosis". Gambi D., Muraro P.A. and Lugaresi A. eds. Springer (Milano, Italy), pp 3-10.
164. Vergelli M., **Massacesi L.**, McFarland H. (2000). Immunopathogenesis of Multiple Sclerosis In "T cell autoimmunity in Multiple Sclerosis". M. Londei ed., Landes Bioscience (Georgetown, Texas, USA), pp.133-148.
165. **Massacesi L.** (2000). Patogenesi della sclerosi multipla: meccanismo di cronicizzazione delle lesioni infiammatorie. In "Aspetti Immunologici e Terapeutici della Sclerosi Multipla"- C. Fieschi ed., UTET Periodici Scientifici (Milano), pp. 2-6.
166. Papini AM, Nardi, E, Mazzucco S, Mazzanti B, Traggia E, Ballerini C, Kalbacher H, Beck H, Chelli M, Ginanneschi M, **Massacesi L**, Vergelli M (2002). Lipophilic modifications of peptide epitopes: T-cell response and susceptibility to peptidases. In Peptides for the New Millennium, Fields G, James P.Tam, Barany G, Eds: 697-699.
167. Mancardi GL, Murialdo A, Saccardi R, Pagliai F, Gualandi F, Marmont A, Inglese M, Bruzzi P, Sormiani MP, Filippi, M., Marrosu M.G., Meucci G., **Massacesi L**, Bertolotto A, Lugaresi A., Morelli E., Filippi M e l' Italian GITMO-NEURO Intergroup sul Trapiantato Autologo di cellule staminali ematopoietiche nella sclerosi multipla (2005). Il trapianto autologo di midollo osseo Intensa immunosoppressione seguita da trapianto autologo di cellule staminali in pazienti con forma grave di SM: dati clinici e RM. In L'interferone beta ed altre possibilità terapeutiche. L Durelli Ed., Excerpta Medica Elsevier (Milano), pp 97-106.
168. G.L. Mancardi, R. Saccardi, A. Murialdo, F. Pagliai, F. Gualandi, A. Marmont, M. Inglese, P. Bruzzi, M.P. Sormani, M.G. Marrosu, G. Meucci, **L. Massacesi**, A. Bertolotto, A. Lugaresi, E. Merelli, M. Filippi (2004) Intense Immunosuppression Followed by Autologous Stem Cell Transplantation in Severe Multiple Sclerosis Cases. In Stem Cell Therapy for Autoimmune Diseases, R. Burt ed.. CRC Press, Boca Raton.

Other extended papers

169. Amaducci L. e **Massacesi L.**(1981). Modificazioni neurochimiche e prospettive di farmacologia sperimentale e clinica nella sclerosi multipla. Atti del XXII° congresso della Società Italiana di Neurologia: 197-206.
170. Cambi F., **Massacesi L.** and Amaducci L. (1982). La sclerosi multipla malattia degli anticorpi senza senso. Aggiornamento del Medico 1 (5): 39-45.
171. Amato M.P., **Massacesi L.** and Amaducci L. (1996). Clinical outcome measurements in Multiple Sclerosis trials. MS

- Forum. Int. MS Journal. 3(1) : 19-27.
172. **Massacesi L.** (2000). Correlati biologici e di laboratorio della patologia neuroimmune. In Atti del Convegno "Impiego delle Immunoglobuline E.V. in neurologia: attualità e prospettive".
 173. **Massacesi L.** and Vergelli M (2001). Experimental autoimmune encephalomyelitis as a model of multiple sclerosis.
 174. **Massacesi L.** Ed. (2013). Percorsi assistenziali del paziente con Sclerosi Multipla. Maya Idee (Verona).
 175. **Massacesi L.** (2013). Ruolo delle Agenzie regolatorie nel percorso autorizzativo dei farmaci neurologici in Europa. Sclerosi Multipla news 4 (14): 4-7.
 176. 8. Mechi C., Repice A., Di Gioia M., Magnani E., Vuolo L., Bandini G., **Massacesi L.** (2014). Fingolimod therapy in a patient with idiopathic thrombocytopenic purpura. About Medicine 11: 23-25.
 177. 9. Sclerosi Multipla e gender medicine: position paper to practice (2015). Amato MP, Iudice A, **Massacesi L.**, Ulivelli M. eds. Maya Idee (Verona).

I herewith authorize processing of my personal data.

"Il sottoscritto è a conoscenza che, ai sensi dell'art 26 della Legge 15/68, le dichiarazioni mendaci, la falsità negli atti e l'uso di atti falsi sono puniti ai sensi del codice penale e delle leggi speciali. Inoltre il/la sottoscritto/a autorizza al trattamento dei dati personali, secondo quanto previsto dal D.L. 196/03 e dal nuovo regolamento generale sulla protezione dei dati n. 679/2016 e successive modifiche o integrazioni"

Florence, August 22, 2022

Luca Massacesi

A handwritten signature in black ink that reads "Luca Massacesi". The signature is written in a cursive, flowing style.